Wedbush Maintains Outperform on Astria Therapeutics, Raises Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has maintained an Outperform rating on Astria Therapeutics (NASDAQ:ATXS) and increased the price target from $17 to $22.
March 26, 2024 | 1:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Laura Chico reaffirmed an Outperform rating on Astria Therapeutics and raised the price target from $17 to $22.
The increase in price target by a reputable analyst like Laura Chico suggests a strong bullish sentiment towards Astria Therapeutics. This is likely to positively influence investor perception and could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100